Meeting
2017 Genitourinary Cancers Symposium
Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
Authors
Igor Stukalin
Tom Baker Cancer Centre, Calgary, AB, Canada
Igor Stukalin , Connor Wells , Anna Paola Fraccon , Felice Pasini , Camillo Porta , Raphael Brandao Moreira , Sandy Srinivas , I. Alex Bowman , James Brugarolas , Jae-Lyun Lee , Frede Donskov , Benoit Beuselinck , Aristotelis Bamias , Brian I. Rini , Hao-Wen Sim , Neeraj Agarwal , Sun Young Rha , Ravindran Kanesvaran , Toni K. Choueiri , Daniel Yick Chin Heng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 498)
DOI
10.1200/JCO.2017.35.6_suppl.498
Abstract #
498
Poster Bd #
F14
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).
First Author: Giuseppe Procopio
Poster
2016 Genitourinary Cancers Symposium
Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.
First Author: Daniel Yick Chin Heng
Poster
2015 Genitourinary Cancers Symposium
Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.
First Author: Daniel Yick Chin Heng
Poster
2023 ASCO Genitourinary Cancers Symposium
The survival outcomes of metastatic non-clear cell renal cell carcinoma in the immunotherapy era: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail Mutahar Al-Ezzi